---
title: "Eton Gains on Acquiring Right to Baby Medicine"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277489776.md"
description: "Eton Pharmaceuticals, Inc. has acquired U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas. HEMANGEOL is an Orphan Drug for treating proliferating infantile hemangioma requiring systemic therapy. CEO Sean Brynjelsen highlighted the importance of this medication and the company's goal of expanding access through their Eton Cares patient support program. This acquisition marks a significant milestone for Eton, achieving ten commercial products and advancing their rare disease portfolio. ETON shares rose 5% to $17.84 following the announcement."
datetime: "2026-03-02T15:22:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277489776.md)
  - [en](https://longbridge.com/en/news/277489776.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277489776.md)
---

# Eton Gains on Acquiring Right to Baby Medicine

Eton Pharmaceuticals, Inc (NASDAQ: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas. HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

“As the only treatment for infantile hemangiomas that require systemic therapy, HEMANGEOL is a critical medication and a strong fit with Eton’s orphan-focused commercial model. We look forward to expanding access to treatment by incorporating our Eton Cares patient support program, which includes our $0 commercial co-pay and best-in-class specialty distribution,” said CEO Sean Brynjelsen, CEO of Eton Pharmaceuticals.

“With this acquisition and the recent approval of DESMODA™ (desmopressin acetate), Eton has now achieved its long-held goal of ten commercial products,” Brynjelsen continued. “This major milestone reflects our continued progress toward building the largest rare disease portfolio in the United States.”

Infantile hemangiomas are non-cancerous vascular tumors which typically appear in the first days or weeks of a newborn’s life. In severe cases, infantile hemangiomas can lead to serious complications including loss of vision, trouble breathing, or physical deformities, and require intervention with systemic therapy. Treatment with HEMANGEOL is typically initiated between ages five weeks to five months and continues for approximately six months. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United  
States.

ETON shares began Monday ahead of the game 85 cents, or 5%, to $17.84.

### Related Stocks

- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)

## Related News & Research

- [Pancreatic cancer pill shown to nearly double overall survival time, drug company says](https://longbridge.com/en/news/282687539.md)
- [Sino Biopharmaceutical Receives US Regulatory Nod to Begin Trials of Anti Tumor Drug](https://longbridge.com/en/news/282121816.md)
- [Novo Nordisk Partners with OpenAI to Boost Drug Development, Delivery](https://longbridge.com/en/news/282641629.md)
- [CRISPR Therapeutics Touts “Second Phase” After Casgevy, Eyes 6 Data Readouts in 6–12 Months](https://longbridge.com/en/news/282582813.md)
- [Oragenics Doses First Patient In Phase 2a Trial For Brain Injury Drug ONP-002](https://longbridge.com/en/news/282660503.md)